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INTRODUCTION

HOSPITAL COURSE, CONT.

Renal-limited ANCA-positive vasculitis is an exceedingly rare
condition with involvement of other organ systems becoming a
distinct possibility with disease progression

 He unfortunately presented again to the hospital 1 month later
after monitoring of his renal function showed progressive
worsening.
 A repeat renal biopsy revealed progression of the disease to
56% of glomeruli with global scarring. The patient was prepared
for hemodialysis due to progression of disease resulting from
failure of treatment

CASE BACKGROUND

A 27 year old with no significant past medical history presents to
the emergency department with the vague abdominal pain, tenpound weight loss, petechial rash on the abdomen and feet, sparing
the soles, and occasional copper-colored urine
These symptoms occurred one month after an assumed viral
upper respiratory infection (URI) with low-grade fever, cough,
rhinorrhea
Patient received his second dose of an mRNA COVID vaccine two
weeks prior to symptom onset
At time of presentation, taking 600 mg Ibuprofen one to two
times daily to treat abdominal pain

Figure 1. Pathogenesis of antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis. ANCA autoantigen proteinase 3 (PR-3) is normally sequestered in the
granules of neutrophils. Environmental stimuli result in neutrophil priming, with
movement of PR3 and MPO to cell surface

HOSPITAL COURSE
Initial workup revealed:

Pertinent Laboratory Findings

Measurement

Result

Normal Range

WBC (K/mcL)

6.1

4.0 – 11.0

HGB (g/dL)

8.7

13.0 – 17.0

MCV (fl)

80

78 – 100

Creatinine (mg/dL)

9.0

0.67 – 1.17

BUN (mg/dL)

71

6 – 20

Albumin (g/dL)

3.0

3.6 – 5.1

The patient was admitted to the hospital, and further
investigation revealed microscopic hematuria, nephrotic-range
proteinuria, positive serum anti-PR-3 antibody, no major electrolyte
imbalances, and negative HIV antigen, HBsAg, and HCV antibody, as
well as abnormal echogenicity of bilateral renal parenchyma with
no evidence of hydronephrosis on ultrasound
The patient subsequently underwent renal biopsy revealing:
Crescentic glomerulonephritis with 18% of
glomeruli demonstrating either global or segmental
scarring
Thin Basement Membrane Nephropathy
He was initiated on IV fluids, high dose steroids and rituximab,
stabilized
Discharged with a plan for continued immunosuppression and
close monitoring of kidney function.

Figure 2. Ultrastructural nature of the glomerular basement membrane in thin
basement membrane nephropathy (TBMN). (A) In the normal adult male kidney, one
can see a uniformly wide glomerular basement membrane (GBM) located between
the fenestrated endothelial cells and the podocyte foot processes. (B) In TBMN, the
GBM does not revel any structural abnormalities, but it is characteristically thinned,
sometimes having only approximately half of the thickness in a normal kidney (A).

Figure 3. Immune drivers and potential therapies of ANCA-associated vasculitis.
Abbreviations: ANCA: anti-neutrophil cytoplasmic antibodies. BAFF: B lymphocyte
activating factor. C5a: complement factor 5 fragment a. NETs: neutrophil
extracellular traps. MPO: myeloperoxidase. PR3: leukocyte proteinase 3.

DISCUSSION

A rising creatinine with hematuria should be treated as a medical
emergency when developing over days to weeks
This case illustrates a patient diagnosed with rapidly progressive
glomerulonephritis due to two separate pathological process
 Glomerular scarring due to autoimmune vasculitis
(Figure 1)
 Thin basement membrane nephropathy (Figure 2)
It remains unclear whether the COVID mRNA vaccine is implicated as
a trigger in the pathogenesis of this diagnosis
Disease pathogenesis is further confounded by preceding viral URI,
although there was no evidence of post-infectious immune complexes
on renal biopsy
B-cells produce ANCA, B-cell Activating Factor (BAFF), Neutrophil
Extracellular Traps (NETs) and Complement 5a (C5a) (Figure 3) which
are implicated in vascular inflammation
Rituximab is the only currently approved therapy for ANCAassociated vasculitis
 Rituximab targets CD20 and halts differentiation of B
lymphocytes into plasma cells, thus reducing
downstream inflammation
Bortezomib, belimumab, abatacept, and avacopan represent
therapies that could have potential benefit in the treatment of ANCAassociated vasculitis (Figure 3)
The kidney is typically the slowest organ to respond to
immunosuppressive therapy in ANCA-associated vasculitides
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